Cargando…

Treatment effectiveness and treatment patterns among rheumatoid arthritis patients after switching from a tumor necrosis factor inhibitor to another medication

OBJECTIVES: After treatment failure with a tumor necrosis factor inhibitor (TNFi), patients with rheumatoid arthritis (RA) can switch to another TNFi (TNFi cyclers) or to a targeted disease-modifying antirheumatic drug (DMARD) with a non-TNFi mechanism of action (non-TNFi switchers). This study comp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bonafede, Machaon MK, Curtis, Jeffrey R, McMorrow, Donna, Mahajan, Puneet, Chen, Chieh-I
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5144914/ https://www.ncbi.nlm.nih.gov/pubmed/27980429 http://dx.doi.org/10.2147/CEOR.S115706

Ejemplares similares

Treatment patterns and economic outcomes in patients with juvenile idiopathic arthritis
por: Marshall, Alexander, et al.
Publicado: (2019)

Effectiveness and Costs Among Rheumatoid Arthritis Patients Treated with Targeted Immunomodulators Using Real-World U.S. Data
por: Gharaibeh, Mahdi, et al.
Publicado: (2020)

Comparison of Healthcare Costs Between Rheumatoid Arthritis Patients Treated with Infused Biologics After Switching from Another Biologic
por: Johnston, Stephen S., et al.
Publicado: (2015)

Comparison of Biologic Disease-Modifying Antirheumatic Drug Therapy Persistence Between Biologics Among Rheumatoid Arthritis Patients Switching from Another Biologic
por: Johnston, Stephen S., et al.
Publicado: (2014)

Cost of tumor necrosis factor blockers per patient with rheumatoid arthritis in a multistate Medicaid population
por: Bonafede, Machaon, et al.
Publicado: (2014)

Care Among Migraine Patients in a Commercially Insured Population
por: Bonafede, Machaon, et al.
Publicado: (2020)

Assessing the Association of Formulary Copayment Changes with Real-World Treatment Patterns in Patients with Rheumatoid Arthritis on Etanercept
por: Bonafede, Machaon, et al.
Publicado: (2020)

Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis
por: Cannon, Grant W., et al.
Publicado: (2016)

Retrospective analysis to describe associations between tumor necrosis factor alpha inhibitors and COPD-related hospitalizations
por: Accortt, Neil A, et al.
Publicado: (2017)

The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor
por: Harrold, Leslie R, et al.
Publicado: (2015)

Efficacy predictors of a second tumor necrosis factor inhibitor in the treatment of rheumatoid arthritis
por: Reams, Jennifer, et al.
Publicado: (2020)

Predictors of Treatment Initiation with Tumor Necrosis Factor-α Inhibitors in Patients with Rheumatoid Arthritis
por: Desai, Rishi J., et al.
Publicado: (2014)

Etanercept‐Methotrexate Combination Therapy Initiators Have Greater Adherence and Persistence Than Triple Therapy Initiators With Rheumatoid Arthritis
por: Bonafede, Machaon, et al.
Publicado: (2015)

Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy
por: Wei, Wenhui, et al.
Publicado: (2017)

Interference of tumor necrosis factor inhibitor treatments on soluble tumor necrosis factor receptor 2 levels in rheumatoid arthritis
por: Yang, Nicole, et al.
Publicado: (2019)

Predictive factors for effective selection of Interleukin-6 inhibitor and tumor necrosis factor inhibitor in the treatment of rheumatoid arthritis
por: Hayashi, Shinya, et al.
Publicado: (2020)

Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis
por: Genovese, Mark C., et al.
Publicado: (2016)

Rheumatoid Arthritis: Refractory to Infliximab, a Tumor Necrosis Factor Inhibitor
por: Solehan, Hana Maizuliana bt, et al.
Publicado: (2011)

Association Between Switching to a High-Deductible Health Plan and Discontinuation of Type 2 Diabetes Treatment
por: Fendrick, A. Mark, et al.
Publicado: (2019)

Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis
por: Sauer, Brian C., et al.
Publicado: (2017)

Response to Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis for Function and Pain is Affected by Rheumatoid Factor
por: Aberumand, Babak, et al.
Publicado: (2014)

Perspectives on Treatment Burden for Methotrexate and Tumor Necrosis Factor Inhibitors Among Patients With Psoriatic Arthritis and Rheumatoid Arthritis: A Qualitative Study
por: Ogdie, Alexis, et al.
Publicado: (2023)

Interleukin-6 inhibitors in the treatment of rheumatoid arthritis
por: Hennigan, Stephanie, et al.
Publicado: (2008)

Signal transduction inhibitors for the treatment of rheumatoid arthritis
por: Tanaka, Yoshiya, et al.
Publicado: (2012)

Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis
por: Gomez-Puerta, Jose A., et al.
Publicado: (2013)

Life-Threatening Gastrointestinal Mucosal Necrosis during Methotrexate Treatment for Rheumatoid Arthritis
por: Tsukada, Tomoya, et al.
Publicado: (2013)

Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis
por: Lillegraven, Siri, et al.
Publicado: (2019)

Development of Rheumatoid Nodules after Anti-Tumor Necrosis Factor-α Treatment with Adalimumab for Rheumatoid Arthritis
por: Shin, Sungsik, et al.
Publicado: (2016)

Cost–utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting
por: Hallinen, Taru A., et al.
Publicado: (2010)

Isoniazid treatment for latent tuberculosis infection is tolerable for rheumatoid arthritis patients receiving tumor necrosis factor inhibitor therapy
por: Sung, Yoon-Kyoung, et al.
Publicado: (2018)

Predictors of biologic-free disease control in patients with rheumatoid arthritis after stopping tumor necrosis factor inhibitor treatment
por: Ghiti Moghadam, Marjan, et al.
Publicado: (2019)

Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis
por: Reed, George W., et al.
Publicado: (2019)

Effect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts Precursors in Rheumatoid Arthritis
por: Perpétuo, Inês P., et al.
Publicado: (2017)

Optimal dose of etanercept in the treatment of rheumatoid arthritis
por: Curtis, Elizabeth Mary, et al.
Publicado: (2014)

Cycling of tumor necrosis factor inhibitors versus switching to different mechanism of action therapy in rheumatoid arthritis patients with inadequate response to tumor necrosis factor inhibitors: a Bayesian network meta-analysis
por: Migliore, Alberto, et al.
Publicado: (2021)

Impact of switching between reference biologics and biosimilars of tumour necrosis factor inhibitors for rheumatoid arthritis: a systematic review and network meta-analysis
por: de Oliveira Ascef, Bruna, et al.
Publicado: (2023)

Genetic Variants Associated with Methotrexate Efficacy and Toxicity in Early Rheumatoid Arthritis: Results from the Treatment of Early Aggressive Rheumatoid Arthritis Trial
por: Aslibekyan, Stella, et al.
Publicado: (2013)

Cost-utility analysis of treatment options after initial tumor necrosis factor inhibitor therapy discontinuation in patients with rheumatoid arthritis
por: Karpes Matusevich, Aliza R, et al.
Publicado: (2021)

Cost-Effectiveness of Global Endometrial Ablation vs. Hysterectomy for Treatment of Abnormal Uterine Bleeding: US Commercial and Medicaid Payer Perspectives
por: Miller, Jeffrey D., et al.
Publicado: (2015)

Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors
por: Tanaka, Toshio, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_dku3f9tss4ubs0furif3j34h1e